Senolytic Compound Screening for Bcl-2 Selectivity and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current senolytic drugs have limitations such as side effects and limited bioavailability, necessitating the development of novel compounds with improved efficacy and safety profiles for treating senescence-associated diseases.
Innovation Solution
Development of pharmaceutical compositions comprising specific compounds of Formula (I) and (II) with structurally diverse senolytic activity, identified through machine learning models and validated for binding to Bcl-2 protein targets, reducing senescent cell burden and senescence-associated gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing senolytic drugs are used, then senescent cell clearance is achieved, but side effects and limited bioavailability occur
Solution Approach 1:
The patent modifies molecular parameters of senolytic compounds by incorporating specific heterocyclic aromatic rings (pyridine, pyrimidine, triazine, thiazole, oxazole) with varying substituents at defined positions, changing chemical properties to improve selectivity and reduce off-target effects while maintaining senescent cell clearance capability
Solution Approach 2:
The invention creates composite molecular structures combining Bcl-2 targeting pharmacophores with heterocyclic aromatic moieties and specific side chains, achieving synergistic effects that enhance senolytic activity while improving safety profiles through multi-functional molecular design
2Reliability
If existing senolytic drugs are used, then senescent cell clearance is achieved, but bioavailability is limited
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by introducing heterocyclic aromatic rings with specific substituents that enhance membrane permeability and metabolic stability, improving oral bioavailability and plasma half-life while preserving senolytic activity
Solution Approach 2:
The heterocyclic aromatic moieties act as intermediary structures that facilitate better absorption and distribution of the senolytic compounds, serving as bridges between the Bcl-2 binding pharmacophore and the biological target while improving bioavailability
3Object-affected harmful factors
If novel compounds are developed to improve efficacy, then safety profile improves, but compound complexity increases
Solution Approach 1:
The patent divides the molecular structure into distinct functional segments: a Bcl-2 binding pharmacophore, heterocyclic aromatic rings with specific substituents, and side chains with defined properties, allowing independent optimization of each segment for safety and activity
Solution Approach 2:
The invention applies local chemical modifications at specific positions of the molecular structure, introducing heterocyclic aromatic rings and substituents only where they provide functional benefit, maintaining overall molecular simplicity while improving safety profiles
Data Source
AI summary
The accumulation of senescent cells is associated with aging, inflammation, and cellular dysfunction. Senolytic drugs can alleviate age-related comorbidities by selectively killing senescent cells. Described herein is a screen of 2,352 compounds for senolytic activity in a model of senescence and trained neural networks to predict the senolytic activities of >800,000 molecules. Methods, systems, and algorithms of the disclosure can enrich for structurally diverse compounds with senolytic activity. Compounds of the disclosure can comprise drug-like compounds which selectively target senescent cells across different senescence models, with more favorable medicinal chemistry properties than, and selectivity comparable to, those of a documented senolytics. Molecular docking simulations of compound binding to several senolytic protein targets, combined with time-resolved fluorescence energy transfer experiments, indicate that these compounds act in part by inhibiting Bcl-2, a regulator of cellular apoptosis. Compounds of the present disclosure can decrease senescent cell burden and mRNA expression of senescence-associated genes.